BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 33875780)

  • 21. Effects of two doses of anti-T lymphocyte globulin-Fresenius given after full-match sibling stem cell transplantation in acute myeloblastic leukemia patients who underwent myeloablative fludarabine/busulfan conditioning.
    Boga C; Yeral M; Gereklioglu C; Asma S; Maytalman E; Aytan P; Kozanoglu I; Sariturk C; Ozdogu H
    Hematol Oncol Stem Cell Ther; 2018 Sep; 11(3):149-157. PubMed ID: 29474820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early tapering of immunosuppressive agents after HLA-matched donor transplantation can improve the survival of patients with advanced acute myeloid leukemia.
    Yang J; Cai Y; Jiang J; Wan L; Bai H; Zhu J; Li S; Wang C; Song X
    Ann Hematol; 2018 Mar; 97(3):497-507. PubMed ID: 29250743
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Battipaglia G; Labopin M; Hamladji RM; Blaise D; Chevallier P; Brissot E; Gerbitz A; Socié G; Afanasyev B; Ciceri F; Meijer E; Koc Y; Cornelissen JJ; Huynh A; Ozdogu H; Maertens J; Paul F; Labussière-Wallet H; Ruggeri A; Aljurf M; Bazarbachi A; Savani B; Nagler A; Mohty M
    Cancer; 2021 Jan; 127(2):209-218. PubMed ID: 33119152
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Prospective Pilot Study of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Ruxolitinib in Patients with Myelofibrosis.
    Morozova EV; Barabanshikova MV; Moiseev IS; Shakirova AI; Barhatov IM; Ushal IE; Rodionov GG; Moiseev SI; Surkova EA; Lapin SV; Vlasova JJ; Rudakova TA; Darskaya EI; Baykov VV; Alyanski AL; Bondarenko SN; Afanasyev BV
    Acta Haematol; 2021; 144(2):158-165. PubMed ID: 32325461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity.
    Mozo Y; Bueno D; Sisinni L; Fernández-Arroyo A; Rosich B; Martínez AP; Benítez-Carabante MI; Alonso L; Uría ML; Heredia CD; Mestre-Duran C; Pascual CFB; Torres J; Losantos I; Escudero A; Ruz-Caracuel B
    Pediatr Hematol Oncol; 2021 May; 38(4):331-345. PubMed ID: 33661711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Umbilical Cord Blood Transplantation without Antithymocyte Globulin Results in Similar Survival but Better Quality of Life Compared with Unrelated Peripheral Blood Stem Cell Transplantation for the Treatment of Acute Leukemia-A Retrospective Study in China.
    Tong J; Xuan L; Sun Y; Huang D; Liu H; Zheng C; Zhu X; Tang B; Song K; Zhang X; Zhang L; Yao W; Lin D; Liu Q; Sun Z
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1541-1548. PubMed ID: 28499936
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study.
    Liu J; Fan Z; Xu N; Ye J; Chen Y; Shao R; Sun Y; Wu Q; Liu Q; Jin H
    Ann Hematol; 2023 Oct; 102(10):2865-2877. PubMed ID: 37474631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical study of allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute lymphocytic leukemia].
    Ma X; Wu DP; Sun AN; Fu ZZ; Tang XW; Wu XJ; Liu YJ; Qiu HY; Miao M; Han Y; Jin ZM; Zhao Y; Xue SL; Wang Y; Chen SN; He GS; Zhou HX; Chang HR
    Zhonghua Xue Ye Xue Za Zhi; 2009 Feb; 30(2):73-6. PubMed ID: 19563014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effect of graft-versus-host disease on relapse and survival in 100 patients after allogeneic hematopoietic stem cell transplantation].
    Deng XR; Ren HY; Cen XN; Wang LH; Liang ZY; Wang WS; Qiu ZX; Ou JP; Xu WL; Wang MJ; Li Y; Yin Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):994-8. PubMed ID: 19698246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia].
    Sun J; Meng FY; Liu QF; Xu D; Xu B; Liu XL
    Ai Zheng; 2003 Dec; 22(12):1321-4. PubMed ID: 14693060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide.
    Zhao JY; Liu SN; Xu LP; Zhang XH; Wang Y; Chen YH; Liu KY; Huang XJ; Mo XD
    Ann Hematol; 2021 Jan; 100(1):169-180. PubMed ID: 33159239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].
    Liu W; Li Y; Qiu ZX; Yin Y; Sun YH; Xu WL; Wang Q; Liang ZY; Dong YJ; Wang LH; Cen QN; Wang MJ; Wang WS; Ou JP; Ren HY
    Zhonghua Nei Ke Za Zhi; 2018 Aug; 57(8):576-581. PubMed ID: 30060329
    [No Abstract]   [Full Text] [Related]  

  • 34. Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation.
    Hamad N; Shanavas M; Michelis FV; Uhm J; Gupta V; Seftel M; Kuruvilla J; Lipton JH; Messner HA; Kim DD
    Am J Hematol; 2015 May; 90(5):392-9. PubMed ID: 25615933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia.
    Wang J; Zhao J; Fei X; Yin Y; Cheng H; Zhang W; Gu J; Yang F; Yang Y; Xue S; Tian Z; He J; Zhang S; Wang X
    Medicine (Baltimore); 2018 Apr; 97(17):e0228. PubMed ID: 29702970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Outcome of allogeneic hematopoietic stem cell transplantation from HLA-matched sibling donor for 41 cases of severe aplastic anemia].
    Chen X; Wei JL; Huang Y; He Y; Yang DL; Jiang EL; Ma QL; Zhou LK; Lin XT; Shen YY; Feng SZ; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2012 Aug; 33(8):610-4. PubMed ID: 23134851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia.
    Mehta RS; Holtan SG; Wang T; Hemmer MT; Spellman SR; Arora M; Couriel DR; Alousi AM; Pidala J; Abdel-Azim H; Ahmed I; Aljurf M; Askar M; Auletta JJ; Bhatt V; Bredeson C; Chhabra S; Gadalla S; Gajewski J; Gale RP; Gergis U; Hematti P; Hildebrandt GC; Inamoto Y; Kitko C; Khandelwal P; MacMillan ML; Majhail N; Marks DI; Mehta P; Nishihori T; Olsson RF; Pawarode A; Diaz MA; Prestidge T; Qayed M; Rangarajan H; Ringden O; Saad A; Savani BN; Seo S; Shah A; Shah N; Schultz KR; Solh M; Spitzer T; Szer J; Teshima T; Verdonck LF; Williams KM; Wirk B; Wagner J; Yared JA; Weisdorf DJ
    Blood Adv; 2019 May; 3(9):1441-1449. PubMed ID: 31053571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [HLA-10/10 matched unrelated donor versus sibling donor hematopoietic stem cell transplantation for adult acute myeloid leukemia].
    Yao JF; Zhang GX; Shen YY; Zhang RL; He Y; Wei JL; Jiang EL; Yang DL; Feng SZ; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):460-466. PubMed ID: 31340617
    [No Abstract]   [Full Text] [Related]  

  • 39. Graft-Versus-Host Disease in Adolescents and Young Adults (15-24 Years Old) After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia in First Complete Remission.
    Vignon M; Andreoli A; Dhédin N; Lengliné E; Masson E; Robin M; Granier C; Larghero J; Schlageter MH; de Latour RP; Socié G; Boissel N
    J Adolesc Young Adult Oncol; 2017 Jun; 6(2):299-306. PubMed ID: 27983886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Mycophenolate mofetil in treatment of graft-versus-host disease after allogeneic hematopoietic cell transplantation: analysis of 44 cases].
    Chen H; Liu KY; Liu DH; Xu LP; Han W; Chen YH; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(30):2127-30. PubMed ID: 19080474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.